Treatment of Difficult-to-Treat Pseudomonas aeruginosa Infections

First-Line Treatment Options

• The International Society for Antimicrobial Chemotherapy recommends ceftolozane/tazobactam and ceftazidime/avibactam as first-line treatment options for invasive infections caused by difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) when the organism is susceptible to these agents 1, 2, 3
• Ceftolozane/tazobactam is preferred for pneumonia, including hospital-acquired and ventilator-associated pneumonia, with a dose of 3 g IV every 8 hours for pneumonia and 1.5 g IV every 8 hours for other infections 1, 2, 3
• Ceftazidime/avibactam is equally effective for non-pulmonary infections with a dose of 2.5 g IV every 8 hours 1, 2, 3

Definition and Diagnosis

• Difficult-to-treat resistance in P. aeruginosa is defined as non-susceptibility to all of the following first-line agents: ceftazidime, cefepime, piperacillin/tazobactam, aztreonam, imipenem/cilastatin, meropenem, levofloxacin, and ciprofloxacin 1, 2, 3

Alternative Treatment Options

• Imipenem/cilastatin/relebactam may retain activity when ceftolozane/tazobactam and ceftazidime/avibactam resistance is present, particularly when metallo-β-lactamases (MBLs) are absent 1, 2, 3
• Cefiderocol is preferred when MBLs are present or as an alternative when other novel agents show resistance 1, 2, 3
• Colistin-based therapy is a last-resort option with a loading dose of 5 mg colistin base activity/kg IV, then 2.5 mg CBA × [1.5 × CrCl + 30] IV every 12 hours 1, 2, 3, 4

Combination Therapy

• Combination therapy should not be routine practice but may be considered on a case-by-case basis, particularly after infectious diseases consultation 1, 2, 3
• Severe infections with limited susceptibility options may require treatment with two in vitro active drugs 5, 4

Site-Specific Considerations

• For pneumonia, the preferred duration of treatment is 10-14 days 4
• For bloodstream infections, the preferred duration of treatment is 10-14 days 4
• For complicated urinary tract infections, the preferred duration of treatment is 5-10 days 4
• For complicated intra-abdominal infections, the preferred duration of treatment is 5-10 days 4

Critical Pitfalls to Avoid

• Do not use older agents empirically, as they are ineffective against DTR-PA 1, 2, 3
• Avoid carbapenem-based combinations for DTR-PA unless meropenem MIC is ≤8 mg/L and extended infusion (>3 hours) is used 5
• Use proper loading dose and maintenance dosing of colistin to avoid subtherapeutic levels 4
• Ceftazidime/avibactam monotherapy may increase the risk of resistance development during therapy 6, 7

Tailoring Therapy

• Therapy must be tailored once culture and susceptibility results are available 1, 2, 3
• Monotherapy with a highly active antipseudomonal β-lactam is preferred in the absence of compelling indications for combination therapy 1, 2, 3

Novel Anti‑Pseudomonal β‑Lactam/β‑Lactamase Inhibitor Guidelines

First‑Line Agents

• The Infectious Diseases Society recommends ceftolozane/tazobactam for multidrug‑resistant Pseudomonas aeruginosa because it shows excellent in‑vitro activity against strains resistant to traditional antipseudomonal agents. 8
• Ceftazidime/avibactam is indicated for non‑pulmonary infections such as bloodstream infections, complicated urinary tract infections, and complicated intra‑abdominal infections (combined with metronidazole for anaerobic coverage). 8
• Avibactam inhibits KPC‑type carbapenemases and some OXA‑48‑like enzymes, extending activity to carbapenem‑resistant Enterobacterales in addition to P. aeruginosa. 9

Second‑Line Agents

• Imipenem/cilastatin/relebactam (1.25 g IV every 6 h) may be used when first‑line novel agents are resistant, provided metallo‑β‑lactamases are absent. [9][10]
• Meropenem/vaborbactam (4 g IV every 8 h) is the first‑line option for KPC‑producing carbapenem‑resistant Enterobacterales; it has limited activity against carbapenem‑resistant P. aeruginosa and is not a primary anti‑pseudomonal agent for DTR strains, but can be useful when KPC‑producing co‑pathogens are present. [9][10]

Treatment Duration

• For complicated intra‑abdominal infections, a course of 5–10 days with a novel β‑lactam/β‑lactamase inhibitor combined with metronidazole is recommended. 8

Antimicrobial Stewardship

• Carbapenems should be restricted to preserve their activity; novel β‑lactam/β‑lactamase inhibitor combinations (ceftolozane/tazobactam and ceftazidime/avibactam) are valuable tools to treat MDR gram‑negative infections while sparing carbapenems. 8
• These novel agents should be reserved for severe infections meeting Sepsis‑3 criteria or for documented DTR P. aeruginosa infections. 11